eIF4E-IN-2 is a highly effective inhibitor of eukaryotic initiation factor 4e (eIF4e). This compound exhibits significant potential in the investigation of eIF4e dependent diseases, particularly in the context of cancer research.
(Z)-4EGI-1 is the Z-isomer of 4EGI-1 and is an inhibitor of eIF4EeIF4G interaction and of translation initiation. (Z)-4EGI-1 effectively binds to eIF4E with an IC50 of 43.5 μM and a Kd value of 8.74 μM. (Z)-4EGI-1 has anticancer activity[1][2]. [1]. Khuloud Takrouri, et al. Structure-activity Relationship Study of 4EGI-1, Small Molecule eIF4EeIF4G Protein-ProteinInteraction Inhibitors. Eur J Med Chem. 2014 Apr 22;77:361-77. [2]. Poornachandran Mahalingam, et al. Synthesis of Rigidified eIF4EeIF4G inhibitor-1 (4EGI-1) Mimetic and Their in Vitro Characterization as Inhibitors of Protein-ProteinInteraction. J Med Chem. 2014 Jun 26;57(12):5094-111.
Tomivosertib, also known as eFT508 is a MNK1 2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1 2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling.